Journey Medical vs Sol-Gel Technologies
DERM and SLGL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DERM and SLGL compare
Sol-Gel Technologies grew revenue faster over the last twelve months (68.0% versus 17.0% for Journey Medical).
Journey Medical keeps more of each dollar of sales as profit, with a net margin of −7.3% compared with −31.6% at Sol-Gel Technologies.
Sol-Gel Technologies scores higher on the StockData Score (10 against 7 for Journey Medical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DERM | SLGL |
|---|---|---|
| Size and price | ||
| Market cap | $122M | – |
| Share price | $4.33 | $55.12 |
| Change, 1 year | −52.3% | 75.0% |
| Change, 5 years | −50.7% | −35.7% |
| Beta (5Y) | 0.68 | 1.00 |
| Employees | 58 | 28 |
| StockData Score | ||
| Total score | 7 | 10 (better) |
| Valuation score | 2 (better) | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 3 | 3 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.8× | – |
| P/B | 3.8× | – |
| Fair value | $5.70 | – |
| Margin of safety | 24.1% | – |
| Growth | ||
| Revenue growth (TTM) | 17.0% | 68.0% (better) |
| Revenue growth, 5Y average | 6.8% | 17.2% (better) |
| Profitability | ||
| Gross margin | 65.9% | – |
| Operating margin | −2.9% (better) | −38.9% |
| Net margin | −7.3% (better) | −31.6% |
| FCF margin | – | 1.4% |
| Return on equity | −17.6% | −15.3% (better) |
| Return on invested capital | −5.2% (better) | −153% |
| Financial health | ||
| Debt / equity | 0.79 (better) | 0.00 |
| Interest coverage | −0.6× | – |
| Current ratio | 1.48 | 10.37 (better) |
| Altman Z-score | 0.55 | – |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 37.8% | 47.5% |
| Held by insiders | 15.3% | 70.2% |
| Insider net buying, 12 months | – | $11.0M |
| Short interest, % of float | 12.9% | 16.3% |
Go deeper
- DERM stock overview
- DERM income statement
- DERM valuation and score
- SLGL stock overview
- SLGL income statement
- SLGL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.